SAN
DIEGO, May 22, 2024 /PRNewswire/
-- Provenance Bio, an alternative protein company, announced
today that its hydroxylated type I collagen protein demonstrates
proof of function by matching the cell adhesion strength of
fibronectin, providing promising scalable and sustainable protein
solutions across various sectors, including pharmaceuticals.
Microbial-based systems for protein production can make proteins
at large manufacturing scales, however, functional animal proteins
which undergo post translational modifications (PTMs), remain
challenging to these expression systems. Provenance's proprietary
precision fermentation platform represents a major biotechnological
achievement by enabling cost-effective, sustainable, and scalable
recombinant solutions for high value markets. Moreover, and equally
important, Provenance Bio's full-length hydroxylated type I
collagen protein demonstrates cell adhesion properties comparable
to fibronectin, a principal protein used for cell culturing in
research and development and pharmaceutical production.
Key Findings:
- Provenance Bio's unique expression system produced
hydroxylated, functional, and bioidentical collagen proteins
- Provenance's hydroxylated collagen proteins promote cell
adhesion at a strength equivalent to traditionally used fibronectin
in cultured human fibroblast cells
- Provenance collagen also performs head-to-head with human
collagen and fibronectin when coated on tissue culture plates
demonstrating similar adherence and dissociation with fibroblast
cells
- Provenance Bio's collagen protein is being produced at an
efficiency that will be cost competitive with animal proteins
"This milestone demonstrates Provenance's ability to
aggressively compete with animal-derived proteins such as collagen
and fibronectin for uses in pharma and other high-margin sectors
today, while addressing ethical, financial and quality concerns
associated with conventional extraction methods," said Michalyn Andrews, co-founder and CEO of
Provenance Bio. "The unique functional attributes of our collagen,
as reflected in these results, will drive innovation and product
development within massive pre-existing markets, such as tissue
cell culture, cosmetics, cell therapies, food ingredients and
manufacturing, leather, bioplastics and other biomaterials."
The global market for cell adhesion proteins is rapidly
expanding, driven by innovations in cell therapies, cultured meat
development, biomaterials, and animal-free products. Provenance
Bio's precision fermentation techniques have enabled the production
of high-value recombinant collagen and gelatin at scale,
positioning the company as a key player in the transition to
sustainable protein solutions.
About Provenance Bio's Precision Fermentation
Platform
Provenance Bio utilizes a unique compartment within the microbial
host cell to produce and modify recombinant animal protein without
the use of any animal products. The system enables precise and
high-yielding protein expression and post-translational
modifications (the addition of certain functional groups to the
protein, such as hydroxylation), for the production of bioactive
proteins at scale. Additionally, the platform supports product
customization to meet specifications such as protein length, bloom
strength, and viscosity for a wide range of applications.
About Cell Adhesion Proteins
Cell adhesion proteins, part of the extracellular matrix (ECM), are
essential to cell and tissue cultures which are widely used in the
life sciences and biomedical research and development. These
proteins, e.g. laminin, fibronectin, and collagen are used for
coating the cell culture vessels to enhance cell attachment and to
stimulate differentiation, migration, structural support and
cellular communication, to ultimately mimic the natural behavior of
the studied cells. According to Grand View Research Report, the
global cell culture protein surface coatings market was valued at
USD 826.5 million in 2022 and is
expected to expand at a compound annual growth rate (CAGR) of
15.29% from 2023 to 2030. Stem cell therapy and regenerative
medicine are two major fields that are driving the industry growth.
Animal derived protein sources have dominated the global industry,
however ethical and religious views are driving demand for
animal-free components.
About Provenance Bio
Provenance is an alternative protein company pioneering molecular
biology tools for sustainable products. The company's proprietary
micro-compartmentalization protein expression platform represents
the future of biomanufacturing. For further information, visit:
https://provenance.bio or email info@provenance.bio
Contact:
Melanie Venter-Roit
+1 858.344.4419
press@provenance.bio
***@venterpr.com
PRLog ID: www.prlog.org/13021169
View original
content:https://www.prnewswire.com/news-releases/provenance-bio-announces-results-for-recombinant-protein-demonstrating-cell-adhesion-functionality-that-can-replace-animal-derived-proteins-302153425.html
SOURCE Provenance Bio